-
NASDAQ:MBRX +48% on major breakthrough to develop a new cancer treatment.
- ARGS +22% on issuance of U.S. patent covering the strain-independent amplification of human immunodeficiency virus.
-
AMAG +19% as FDA grants AMAG Pharma's Makena subcutaneous auto-injector.
-
SEDG +17% on Q4 result.
-
TRIP +15% on Q4 result.
- ATRS +14% as FDA grants AMAG Pharma's Makena subcutaneous auto-injector.
-
SHLM +10% on being acquired by LyondellBasell (LYB).
-
TEVA +9% on Berkshire investment.
-
OMER +8% as OMS721 shows treatment effect in mid-stage HCT-TMA study.
-
AVP +8% on Q4 result.
- CTL +8% on Q4 result.
-
MARA +8% on expanding cryptocurrency mining operations.
-
YNDX +7% on Q4 result.
-
CSCO +7% on Q2 result.
-
CARA +7%.
-
RIOT +6% on entering into a definitive agreement to acquire additional cryptocurrency mining equipment.
-
OSTK +5%.
- DPW +5%.